# From sweet to belligerent in the blink of an eye

P. Brittany Vickery, PharmD, BCPS, BCPP, and Kailey Hoots

How would you handle this case?

Answer the challenge questions at MDedge.com/ psychiatry and see how your colleagues responded Ms. P, age 87, presents with mental status changes, agitation, and combativeness. She has a complex medical history and lengthy medication list. What's causing her change in behavior?

#### **CASE** Combative and agitated

Ms. P, age 87, presents to the emergency department (ED) with her caregiver, who says Ms. P has new-onset altered mental status, agitation, and combativeness.

Ms. P resides at a long-term care (LTC) facility, where according to the nurses she normally is pleasant, well-oriented, and cooperative. Ms. P's medical history includes major depressive disorder, generalized anxiety disorder, hypertension, chronic kidney disease (CKD) stage III, peptic ulcer disease, gastroesophageal reflux disease, coronary artery disease with 2 past myocardial infarctions requiring stents, chronic obstructive pulmonary disease, hyperlipidemia, bradycardia requiring a pacemaker, paroxysmal atrial fibrillation, asthma, aortic stenosis, peripheral vascular disease, esophageal stricture requiring dilation, deep vein thrombosis, and migraines.

Mr. P's medication list includes acetaminophen, 650 mg every 6 hours; ipratropium/albuterol nebulized solution, 3 mL 4 times a day; aspirin, 81 mg/d; atorvastatin, 40 mg/d; calcitonin, 1 spray nasally at bedtime; clopidogrel, 75 mg/d; ezetimibe, 10 mg/d; fluoxetine, 20 mg/d; furosemide, 20 mg/d; isosorbide dinitrate, 120 mg/d; lisinopril, 15 mg/d; risperidone, 0.5 mg/d; magnesium oxide, 800 mg/d; pantoprazole, 40 mg/d; polyethylene glycol, 17 g/d; sotalol, 160 mg/d; olanzapine, 5 mg IM every 6 hours as needed for agitation; and tramadol, 50 mg every 8 hours as needed for headache.

Seven days before coming to the ED, Ms. P was started on ceftriaxone, 1 g/d, for suspected community-acquired pneumonia. At that time, the nursing staff noticed behavioral changes. Soon after, Ms. P began refusing all her medications. Two days before presenting to the ED, Ms. P was started on nitrofurantoin, 200 mg/d, for a suspected urinary tract infection, but it was discontinued because of an allergy.

Her caregiver reports that while at the LTC facility, Ms. P's behavioral changes worsened. Ms. P claimed to be Jesus Christ and said she was talking to the devil; she chased other residents around the facility and slapped medications away from the nursing staff. According to caregivers, this behavior was out of character.

Shortly after arriving in the ED, Ms. P is admitted to the psychiatric unit.

continued

#### Disclosures

Dr. Vickery is Associate Professor, Pharmacy Practice, Wingate University School of Pharmacy, Hendersonville, North Carolina. Kailey Hoots is a Doctor of Pharmacy candidate, Wingate University School of Pharmacy, Hendersonville, North Carolina.

The authors report no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

# Based on Ms. P's presentation, what is the most likely diagnosis?

a) new-onset dementia

- b) delirium of multiple etiologies
- c) dementia with behavioral disturbances
- d) medication-induced confusion

#### The authors' observations

Delirium is a complex, acute alteration in a patient's mental status compared with his/her baseline functioning<sup>1</sup> (*Table 1*<sup>2</sup>). The onset of delirium is quick, happening within hours to days, with fluctuations in mental function. Patients might present with hyperactive, hypoactive, or mixed delirium.3 Patients with hyperactive delirium often have delusions and hallucinations; these patients might be agitated and could become violent with family and caregivers.3 Patients with hypoactive delirium are less likely to experience hallucinations and more likely to show symptoms of sedation.<sup>3</sup> Patients with hypoactive delirium can be difficult to diagnose because it is challenging to interview them and understand what might be the cause of their sedated state. Patients also can exhibit a mixed delirium in which they fluctuate between periods of hyperactivity and hypoactivity.<sup>3</sup>

Suspected delirium should be considered a medical emergency because the outcome could be fatal.<sup>1</sup> It is important to uncover and treat the underlying cause(s) of delirium rather than solely administering antipsychotics, which might mask the presenting symptoms. In an older study, Francis and Kapoor<sup>4</sup> reported that 56% of geriatric patients with delirium had a single definite or probable etiology, while the other 44% had about 2.8 etiologies per patient on average. Delirium risk factors, causes, and factors to consider during patient evaluation are listed in *Table 2*<sup>1,3,5-7</sup> (*page e6*) and *Table 3*<sup>1,3,5-7</sup> (*page e7*).

A synergistic relationship between comorbidities, environment, and medications can

## Table 1 DSM-5 diagnostic criteria for delirium

Disturbance in attention (reduced ability to focus, sustain, or shift attention) and awareness (reduced orientation to the environment)

An additional cognitive disturbance (memory deficit, disorientation, language disturbances, visuospatial or perceptual disturbance)

The disturbance develops over a short period of time (usually hours to days), represents a change from baseline, and tends to fluctuate in severity during the course of the day

There is evidence from the history, physical examination, or laboratory findings that the disturbance is caused by a medical condition, substance intoxication or withdrawal (due to a drug of abuse or a medication), or exposure to a toxin, or is due to multiple etiologies

The changes in attention/awareness and cognition are not better accounted for by a preexisting, established, or evolving neurocognitive disorder

The disturbances do not occur in the context of a severely reduced level of consciousness (eg, coma)

Source: Reference 2

induce delirium.<sup>5</sup> Identifying irreversible and reversible causes is the key to treating delirium. After the cause has been identified, it can be addressed and the patient could return to his/her previous level of functioning. If the delirium is the result of multiple irreversible causes, it could become chronic.

# Which of the following are risk factors for or contributors to delirium?

- a) female sex, macrocytic anemia, dehydration
- b) history of dementia, hypoglycemia, aspirin use
- c) chronic kidney disease, sotalol, recent antibiotics
- d) hepatic disease, history of recent falls, tramadol

# **Clinical Point**

Suspected delirium should be considered a medical emergency because the outcome could be fatal



# Table 2

# Risk factors and medical causes to consider in a delirium workup

Risk factors	Dementia or cognitive impairment CNS disease/cardiovascular events Age >65 History of delirium History of stroke Neurologic disease Falls or a gait disorder Multiple comorbidities Male sex Chronic kidney disease Hepatic disease	
Medical causes of delirium	Alcohol withdrawal Sensory impairment or deprivation (hearing or vision) Sustained sleep deprivation Decreased physical activity or immobilization Metabolic derangement or dehydration Renal or hepatic dysfunction Emotional distress Poor nutrition Substance abuse Surgery Pain Environment (ICU admission) Acute neurologic disease (stroke, intracranial hemorrhage, meningitis, encephalitis, post-ictal state) Infections (urinary tract infections, pneumonia, HIV) Anemia Arrhythmias Dehydration Hypoglycemia Hyporthermia Hyperthermia Hypertension Trauma Shock	
HIV: human immunodeficiency virus; ICU: intensive care unit		

Source: References 1,3,5-7

## **EVALUATION** Cardiac dysfunction

Ms. P undergoes laboratory testing. The results include: white blood cell count,  $5.9/\mu$ L; hemoglobin, 13.6 g/dL; hematocrit, 42.6%; platelets,  $304 \times 103/\mu$ L; sodium, 143 mEq/L; potassium, 3.2 mEq/L; chloride, 96 mEq/L; carbon dioxide, 23 mEq/L; blood glucose, 87 mg/dL; creatinine, 1.2 mg/dL; estimated creatinine clearance (eCrCl) level of 33 mL/min/1.73 m<sup>2</sup>; calcium, 9.5 mg/dL; albumin, 3.6 g/dL; liver enzymes within normal limits; thyroid-stimulating hormone, 0.78 mIU/L; vitamin B<sub>12</sub>, 995 pg/mL; folic acid, 16.6 ng/mL; vitamin D, 31 pg/mL; and rapid

plasma reagin: nonreactive. Urinalysis is unremarkable, and no culture is performed. Urine drug screening/toxicology is positive for the benzodiazepines that she received in the ED (oral alprazolam 0.25 mg given once and oral lorazepam 0.5 mg given once).

Electrocardiogram (ECG) shows atrial flutter/tachycardia with rapid ventricular response, marked left axis deviation, nonspecific ST- and T-wave abnormality, QT/ QTC of 301/387 ms, and ventricular rate 151 beats per minute. A CT scan of the head and brain without contrast shows mild atrophy

#### **Clinical Point**

A synergistic relationship between comorbidities, environment, and medications can induce delirium

## Table 3

# Medications to consider in a delirium workup<sup>a</sup>

Analgesics • nonsteroidal anti-inflammatory medications	<ul> <li>opioids (especially meperidine)</li> </ul>		
Antibiotics • acyclovir • aminoglycosides • amphotericin B • cephalosporins • fluoroquinolones • isoniazid	<ul> <li>interferon therapies</li> <li>linezolid, macrolides</li> <li>metronidazole</li> <li>penicillins</li> <li>rifampin</li> <li>sulfonamides</li> </ul>		
Anticholinergics <ul> <li>atropine</li> <li>antihistamines</li> <li>benztropine</li> </ul>	<ul><li>diphenhydramine</li><li>trihexyphenidyl</li></ul>		
Antiepileptics • carbamazepine • levetiracetam	<ul><li> phenytoin</li><li> valproic acid</li></ul>		
Antidepressants <ul> <li>tricyclic antidepressants</li> <li>selective serotonin reuptake inhibitors</li> </ul>	• mirtazapine		
Barbiturates			
Benzodiazepines			
Cardiovascular agents <ul> <li>antiarrhythmics</li> <li>beta blockers</li> <li>clonidine</li> </ul>	• digoxin • diuretics • methyldopa		
Corticosteroids			
Dopamine agonists • amantadine • bromocriptine • levodopa	• pramipexole • ropinirole		
Gastrointestinal agents <ul> <li>antiemetics</li> <li>antispasmodics</li> </ul>	<ul><li>H2 receptor blockers</li><li>loperamide</li></ul>		
Herbals • St. John's wort • valerian	• mandrake • jimson weed		
Muscle relaxants • baclofen	cyclobenzaprine		
Other CNS-active agents • disulfiram • carbidopa-levodopa • cholinesterase inhibitors	<ul> <li>lithium</li> <li>phenothiazines (fluphenazine, chlorpromazine)</li> </ul>		

# **Clinical Point**

Potential causes of behavioral or cognitive changes should be ruled out in a step-by-step approach

<sup>a</sup>This list is not inclusive. Many of the drugs listed serve as examples of medications in the drug class listed or have been implicated in case reports

Source: References 1,3,5-7

and chronic white matter changes and no acute intracranial abnormality. A two-view chest radiography shows no acute cardiopulmonary findings. Her temperature is 98.4°F; heart rate is 122 beats per minute; respiratory rate is 20 breaths per minute; blood pressure is 161/98 mm Hg; and oxygen saturation is 86% on room air.

Based on this data, Ms. P's cardiac condition seems to be worsening, which is thought to be caused by her refusal of furosemide, lisinopril, isosorbide, sotalol, clopidogrel, and aspirin. The treatment team plans to work on compliance to resolve these cardiac issues and places Ms. P on 1:1 observation with a sitter and music in attempt to calm her.

#### The authors' observations

Many factors can contribute to behavioral or cognitive changes in geriatric patients. Often, a major change noted in an older patient can be attributed to new-onset dementia, dementia with behavioral disturbances, delirium, depression, or acute psychosis. These potential causes should be considered and ruled out in a step-by-step progression. Because patients are unreliable historians during acute distress, a complete history from family or caregivers and exhaustive workup is paramount.

#### **TREATMENT** Medication adjustments

In an attempt to resolve Ms. P's disruptive behaviors, her risperidone dosage is changed to 0.5 mg twice daily. Ms. P is encouraged to use the provided oxygen to raise her saturation level.

On hospital Day 3, a loose stool prompts a *Clostridium difficile* test as a possible source of delirium; however, the results are negative.

On hospital Day 4, Ms. P is confused and irritable overnight, yelling profanities at staff, refusing care, inappropriately disrobing, and having difficulty falling asleep and staying asleep. Risperidone is discontinued because it appears to have had little or no effect on Ms. P's disruptive behaviors. Olanzapine, 10 mg/d, is initiated with mirtazapine, 7.5 mg/d, to help with mood, appetite, and sleep. Fluoxetine is also discontinued because of a possible interaction with clopidogrel.

On hospital Days 6 to 8, Ms. P remains upset and unable to follow instructions. Melatonin is initiated to improve her sleep cycle. On Day 9, she continues to decline and is cursing at hospital staff; haloperidol is initiated at 5 mg every morning, 10 mg at bedtime, and 5 mg IM as needed for agitation. Her sleep improves with melatonin and mirtazapine. IV hydration also is initiated. Ms. P has a slight improvement in medication compliance. On Day 11, haloperidol is increased to 5 mg in the morning, 5 mg in the afternoon, and 10 mg at bedtime. On Day 12, haloperidol is changed to 7.5 mg twice daily; a slight improvement in Ms. P's behavior is noted.

On hospital Day 13, Ms. P's behavior declines again. She screams profanities at staff and does not recognize the clinicians who have been providing care to her. The physician initiates valproic acid, 125 mg, 3 times a day, to target Ms. P's behavioral disturbances. A pharmacist notes that the patient's sotalol could be contributing to Ms. P's psychiatric presentation, and that based on her eCrCl level of 33 mL/min/ 1.73 m<sup>2</sup>, a dosage adjustment or medication change might be warranted.

On Day 14, Ms. P displays erratic behavior and intermittent tachycardia. A cardiac consultation is ordered. A repeat ECG reveals atrial fibrillation with rapid rate and a QT/QTc of 409/432 ms. Ms. P is transferred to the telemetry unit, where the cardiologist discontinues sotalol because the dosage is not properly renally adjusted. Sotalol hydrochloride has been associated with life-threatening ventricular tachycardia.<sup>8</sup> Diltiazem, 30 mg every 6 hours is initiated to replace sotalol.

By Day 16, the treatment team notes improved cognition and behavior. On Day 17, the cardiologist reports that Ms. P's atrial fibrillation is controlled. An ECG reveals mild left ventricular hypertrophy, an ejection fraction of 50% to 55%, no stenosis in the mitral or tricuspid valves, no valvular pulmonic stenosis, and moderate aortic sclerosis. Cardiac markers also are evaluated (creatinine phosphokinase: 105 U/L; creatinine kinase–MB fraction: 2.6 ng/mL; troponin: 0.01 ng/mL; pro-B-type natriuretic peptide: 2,073 pg/mL); and myocardial infarction is ruled out.

On Day 19, Ms. P's diltiazem is consolidated to a controlled-delivery formulation, 180 mg/d, along with the addition of metoprolol,

# Clinical Point

During acute distress, patients are unreliable historians; a complete history from family or caregivers is critical 12.5 mg twice daily. Ms. P is transferred back to the psychiatric unit.

#### **OUTCOME** Gradual improvement

On Days 20 to 23, Ms. P shows remarkable progress, and her mental status, cognition, and behavior slowly return to baseline. Haloperidol and valproic acid are tapered and discontinued. Ms. P is observed to be healthy and oriented to person, place, and time.

On Day 25, she is discharged from the hospital, and returns to the LTC facility.

#### The authors' observations

Ms. P's delirium was a combination of her older age, non-renally adjusted sotalol, and CKD. At admission, the hospital treatment team first thought that pneumonia or antibiotic use could have caused delirium. However, Ms. P's condition did not improve after antibiotics were stopped. In addition, several chest radiographs found no evidence of pneumonia. It is important to check for any source of infection because infection is a common source of delirium in older patients.1 Urine samples revealed no pathogens, a C. difficile test was negative, and the patient's white blood cell counts remained within normal limits. Physicians began looking elsewhere for potential causes of Ms. P's delirium.

Ms. P's vital signs ruled out a temperature irregularity or hypertension as the cause of her delirium. She has a slightly low oxygen saturation when she first presented,

#### **Related Resources**

- Marcantonio ER. Delirium in hospitalized older adults. N Engl J Med. 2017;377:1456-1466.
- Inouye SK, Westendorp RGJ, Saczynski JS. Delirium in elderly people. Lancet. 2014;383(9920):911-922.

#### **Drug Brand Names**

Acyclovir • Zovirax Alprazolam • Niravam, Xanax Amantadine • Symmetrel Amphotericin B • Abelcet Atorvastatin • Lipitor Atropine • Atropen Baclofen • EnovaRX-Baclofen Benztropine • Cogentin Bromocriptine • Cycloset Calcitonin • Miacalcin Carbamazepine • Tegretol Carbidopa-levodopa • Duopa Ceftriaxone • Rocephin Chlorpromazine • Thorazine Clonidine • Catapres Clopidogrel • Plavix Cyclobenzaprine • Amrix Digoxin • Lanoxin Diltiazem • Cardizem Disulfiram • Antabuse Ezetimibe • Zetia Fluoxetine • Prozac Fluphenazine • Prolixin Furosemide • Lasix Haloperidol • Haldol Ipratropium/albuterol nebulized solution • **Combivent Respimat** 

Isoniazid • Isotamine Isosorbide nitrate • Dilatrate Levetiracetam • Keppra Levodopa • Stalevo Linezolid • Zyvox Lisinopril • Zestril Lithium • Eskalith, Lithobid Lorazepam • Ativan Magnesium Oxide • Mag-200 Meperidine • Demerol Methyldopa • Aldomet Metoprolol • Lopressor Metronidazole • Flagyl Mirtazapine • Remeron Nitrofurantoin • Macrobid Olanzapine • Zvprexa Pantoprazole • Protonix Phenytoin • Dilantin Pramipexole • Mirapex Rifampin • Rifadin Risperidone • Risperdal Ropinirole • Requip Sotalol hydrochloride • Betapace AF Tramadol • Ultram Trihexyphenidyl • Trihexane Valproic acid • Depakote

# **Clinical Point**

Chronic kidney disease can interrupt the normal pharmacokinetics of medications

but this quickly returned to normal with administration of oxygen, which ruled out hypoxemia. Laboratory results concluded that Ms. P's glucose levels were within a normal range and she had no electrolyte imbalances. A head CT scan showed slight atrophy of white matter that is consistent with Ms. P's age. The head CT scan also showed that Ms. P had no acute condition or head trauma.

continued

# **Bottom Line**

Delirium is a complex disorder that often has multiple causes, both reversible and irreversible. A "process of elimination" approach should be used to accurately identify and manage delirium. If a patient with delirium has little to no response to antipsychotic medications, the underlying cause or causes likely has not yet been addressed, and the evaluation should continue.

#### **Clinical Point**

Ms. P's delirium was a combination of her older age, non-renally adjusted sotalol, and CKD

In terms of organ function, Ms. P was in relatively healthy condition other than paroxysmal atrial fibrillation and CKD. Chronic kidney disease can interrupt the normal pharmacokinetics of medications. Reviewing Ms. P's medication list, several agents could have induced delirium, including antidepressants, antipsychotics, cardiovascular medications (beta blocker/antiarrhythmic [sotalol]), and opioid analgesics such as tramadol.5 Ms. P's condition did not improve after discontinuing fluoxetine, risperidone, or olanzapine, although haloperidol was started in their place. Ms. P scored an 8 on the Naranjo Adverse Drug Reaction Probability Scale, indicating this event was a probable adverse drug reaction.9

#### **Identifying a cause**

This was a unique case where sotalol was identified as the culprit for inducing Ms. P's delirium, because her age and CKD are irreversible. It is important to note that antiarrhythmics can induce arrhythmias when present in high concentrations or administered without appropriate renal dose adjustments. Although Ms. P's serum levels of sotalol were not evaluated, because of her renal impairment, it is possible that toxic levels of sotalol accumulated and lead to arrhythmias and delirium. Of note, a cardiologist was consulted to safely change Ms. P to a calcium channel blocker so she could undergo cardiac monitoring. With the addition of diltiazem and metoprolol, the patient's delirium subsided and her arrhythmia was controlled. Once the source of Ms. P's delirium had been identified, antipsychotics were no longer needed.

#### References

- Fong TG, Tulebaev SR, Inouye SK. Delirium in elderly adults: diagnosis, prevention, and treatment. Nat Rev Neurol. 2009;5(4):210-220.
- Diagnostic and statistical manual of mental disorders, fifth edition. Washington, DC: American Psychiatric Association; 2013.
- American Psychiatric Association. Practice guideline for the treatment of patients with delirium. Am J Psychiatry. 1999;156(suppl 5):1-20.
- 4. Francis J, Kapoor WN. Delirium in hospitalized elderly. J Gen Intern Med. 1990;5(1):65-79.
- Alagiakrishnan K, Wiens CA. An approach to drug induced delirium in the elderly. Postgrad Med J. 2004;80(945): 388-393.
- Cook IA. Guideline watch: practice guideline for the treatment of patients with delirium. Arlington, VA: American Psychiatric Publishing; 2004.
- Bourgeois J, Ategan A, Losier B. Delirium in the hospital: emphasis on the management of geriatric patients. Current Psychiatry. 2014;13(8):29,36-42.
- 8. Betapace AF [package insert]. Zug, Switzerland: Covis Pharma; 2016.
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245.